ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

AstraZeneca, Amgen and CSPC Pharmaceutical Group side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

AstraZeneca×Amgen×CSPC Pharmaceutical Group×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AstraZenecaAmgenCSPC Pharmaceutical Group
studies on the registry4,1971,088357
open to participants now29850172
phase 3 studies under way2005065
reach primary completion within a year1683555
programswith a study of their own in two years119+5 named only2468+3 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAstraZenecaAmgenCSPC Pharmaceutical Group
Phase 1

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%

Amgen: 8 of its 24 programs at phase 1

  1. AMG 691phase 1
  2. AMG 127phase 1
  3. etakafusp alfaphase 1
  4. Pan-KRAS Inhibitor AMG 410phase 1
  5. tambotatug pelitecanphase 1

and 3 more — sign in to see them all

33%

CSPC Pharmaceutical Group: 16 of its 68 programs at phase 1

  1. JMT206phase 1
  2. SYH2082phase 1
  3. JMT106phase 1
  4. paclitaxel cationic liposome for injectionphase 1
  5. palbociclibphase 1

and 11 more — sign in to see them all

24%
Phase 2

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%

Amgen: 1 of its 24 programs at phase 2

  1. AMG 732phase 2
4%

CSPC Pharmaceutical Group: 26 of its 68 programs at phase 2

  1. Anti-PD-1/IL-15 Fusion Protein JMT108phase 2
  2. SYS6006 COVID-19 vaccinephase 2
  3. ATM Inhibitor SYH2051phase 2
  4. SYH2069phase 2
  5. SYH2070phase 2

and 21 more — sign in to see them all

38%
Phase 3

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%

Amgen: 7 of its 24 programs at phase 3

  1. maridebart cafraglutidephase 3
  2. tarlatamabphase 3
  3. xaluritamigphase 3
  4. sotorasibphase 3
  5. olpasiranphase 3

and 2 more — sign in to see them all

29%

CSPC Pharmaceutical Group: 25 of its 68 programs at phase 3

  1. Anti-EGFR Antibody-drug Conjugate CPO301phase 3
  2. Docetaxelphase 3
  3. enlonstobartphase 3
  4. becotatugphase 3
  5. anbenitamabphase 3

and 20 more — sign in to see them all

37%
Approved, new studies

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%

Amgen: 8 of its 24 programs at approved, new studies

  1. inebilizumabapproved, new study
  2. blinatumomabapproved, new study
  3. apremilastapproved, new study
  4. evolocumabapproved, new study
  5. romiplostimapproved, new study

and 3 more — sign in to see them all

33%

CSPC Pharmaceutical Group: 1 of its 68 programs at approved, new studies

  1. Tenecteplaseapproved, new study
1%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
AstraZeneca60 readouts · 16 phase 3

AstraZeneca, Nov ’26: 4 programs whose next study reaches primary completion

  1. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  2. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  3. durvalumabapproved, new study · Nov 30 · NCT07081633
  4. tremelimumabphase 3 · Nov 30 · NCT07081633

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 13 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 8 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
Amgen12 readouts · 3 phase 3·

Amgen, Dec ’26: 1 program whose next study reaches primary completion

  1. sotorasibphase 3 · Dec 17 · NCT04185883

Amgen, Jan ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. AMG 732phase 2 · Jan 6 · NCT06401044
  2. apremilastapproved, new study · Jan 10 · NCT07908641
  3. romosozumabapproved, new study · Jan 14 · NCT07811999
  4. maridebart cafraglutidephase 3 · Jan 21 · NCT06858839

Amgen, Feb ’27: 1 program whose next study reaches primary completion

  1. xaluritamigphase 3 · Feb 17 · NCT06613100

Amgen, Mar ’27: 1 program whose next study reaches primary completion

  1. AMG 691phase 1 · Mar 17 · NCT07745907

Amgen, Apr ’27: 2 programs whose next study reaches primary completion

  1. inebilizumabapproved, new study · Apr 13 · NCT05549258
  2. tarlatamabphase 3 · Apr 24 · NCT06598306

Amgen, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. evolocumabapproved, new study · May 29 · NCT05284747
·

Amgen, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. afliberceptphase 3 · Jul 31 · NCT07614776
··

Amgen, Oct ’27: 1 program whose next study reaches primary completion

  1. AMG 127phase 1 · Oct 2 · NCT07590193
CSPC Pharmaceutical Group39 readouts · 6 phase 3

CSPC Pharmaceutical Group, Nov ’26: 3 programs whose next study reaches primary completion

  1. SYH2061phase 1 · Nov 24 · NCT07241910
  2. Anti-EGFR Antibody-drug Conjugate CPO301phase 3 · Nov 30 · NCT07256509
  3. Anti-PD-1/IL-15 Fusion Protein JMT108phase 2 · Nov 30 · NCT07280832

CSPC Pharmaceutical Group, Dec ’26: 6 programs whose next study reaches primary completion, 2 in phase 3

  1. anbenitamabphase 3 · Dec 16 · NCT06747338
  2. Docetaxelphase 3 · Dec 16 · NCT06747338
  3. glumetinibphase 3 · Dec 25 · NCT06525350
  4. paliperidoneno phase · Dec 31 · NCT07493551
  5. SYH2059phase 2 · Dec 31 · NCT07510958

and 1 more — sign in to see them all

CSPC Pharmaceutical Group, Jan ’27: 4 programs whose next study reaches primary completion

  1. SYH2056phase 1 · Jan 30 · NCT07771777
  2. SYH2082phase 1 · Jan 30 · NCT07532655
  3. SYS6005phase 1 · Jan 30 · NCT06958679
  4. SYH2062phase 2 · Jan 31 · NCT07940075

CSPC Pharmaceutical Group, Feb ’27: 4 programs whose next study reaches primary completion

  1. SYH2072phase 2 · Feb 1 · NCT07647783
  2. SYH2092phase 1 · Feb 9 · NCT07776041
  3. JMT206phase 1 · Feb 28 · NCT07840729
  4. SYS6040phase 1 · Feb 28 · NCT06970795

CSPC Pharmaceutical Group, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. A zoster mRNA vaccine SYS6017phase 2 · Mar 10 · NCT07354659
  2. becotatugphase 3 · Mar 26 · NCT06380348
  3. SYS6041phase 2 · Mar 28 · NCT07744763

CSPC Pharmaceutical Group, Apr ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. enlonstobartphase 3 · Apr 0 · NCT06136988
  2. CPO-107phase 2 · Apr 1 · NCT07029139
  3. SYHX1901phase 3 · Apr 28 · NCT06943950
  4. SYH2070phase 2 · Apr 30 · NCT07695597
  5. SYH2085phase 2 · Apr 30 · NCT07798193

CSPC Pharmaceutical Group, May ’27: 1 program whose next study reaches primary completion

  1. anbenitamab repodatecanphase 3 · May 29 · NCT07545044

CSPC Pharmaceutical Group, Jun ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. ATM Inhibitor SYH2051phase 2 · Jun 15 · NCT06775236
  2. bempedoic acidphase 3 · Jun 30 · NCT07623915

CSPC Pharmaceutical Group, Jul ’27: 4 programs whose next study reaches primary completion

  1. ocankitugphase 3 · Jul 1 · NCT07418736
  2. SYH2053phase 3 · Jul 15 · NCT07938034
  3. SYS6045phase 2 · Jul 30 · NCT07122063
  4. CHO cellphase 2 · Jul 31 · NCT07892989

CSPC Pharmaceutical Group, Aug ’27: 2 programs whose next study reaches primary completion

  1. SYHX2008phase 3 · Aug 1 · NCT06505395
  2. JMT203phase 2 · Aug 14 · NCT06868849

CSPC Pharmaceutical Group, Sep ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Aripiprazoleno phase · Sep 5 · NCT07547384
  2. SYH2069phase 2 · Sep 28 · NCT07796477
  3. Tenecteplaseapproved, new study · Sep 30 · NCT07201688

CSPC Pharmaceutical Group, Oct ’27: 2 programs whose next study reaches primary completion

  1. palbociclibphase 1 · Oct 0 · NCT06941142
  2. Sirolimusphase 3 · Oct 0 · NCT06941142
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 24, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Amgen

New programs 0

None

Reached a new phase 0

None

Study stopped 1

Primary completion later 5

CSPC Pharmaceutical Group

New programs 6

  • SYH9061phase 2 · first study · Nov 2 · Idiopathic Pulmonary Fibrosis
  • SYS6062phase 2 · first study · Oct 20 · Stomach Neoplasms
  • CHO cellphase 2 · first study · Oct 19 · COVID-19
  • SYH2066phase 2 · first study · Oct 11 · Respiratory Syncytial Virus Infections
  • Generic Drugphase 3 · first study · Sep 28 · Triple Negative Breast Neoplasms
  • SYS6088phase 2 · first study · Sep 20 · Neoplasms

Reached a new phase 3

  • SYH2072phase 2 · Oct 28 · Hyperaldosteronism
  • SYH2069phase 2 · Aug 25 · Obesity
  • SYH2085phase 2 · Aug 25 · Influenza, Human

Study stopped 0

None

Primary completion later 2

Where they overlap

Conditions where at least two of them have programs: 57 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionAstraZenecaAmgenCSPC Pharmaceutical Group
Carcinoma, Non-Small-Cell Lungall three · compare here

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 16 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 11 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

Amgen in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. sotorasibphase 3
  2. Pan-KRAS Inhibitor AMG 410phase 1
  3. tambotatug pelitecanphase 1
  4. romiplostimapproved, new study

Their studies: Amgen’s studies of Carcinoma, Non-Small-Cell Lung in search

CSPC Pharmaceutical Group in Carcinoma, Non-Small-Cell Lung: 10 programs

  1. Anti-EGFR Antibody-drug Conjugate CPO301phase 3
  2. Docetaxelphase 3
  3. enlonstobartphase 3
  4. becotatugphase 3
  5. glumetinibphase 3

and 5 more — sign in to see them all

Their studies: CSPC Pharmaceutical Group’s studies of Carcinoma, Non-Small-Cell Lung in search

Prostatic Neoplasmsall three · compare here

AstraZeneca in Prostatic Neoplasms: 13 programs

  1. saruparibphase 3
  2. capivasertibphase 3
  3. zibotentanphase 3
  4. Actinium-225phase 3
  5. zadavotide guraxetanphase 2

and 8 more — sign in to see them all

Their studies: AstraZeneca’s studies of Prostatic Neoplasms in search

Amgen in Prostatic Neoplasms: 2 programs

  1. tarlatamabphase 3
  2. xaluritamigphase 3

Their studies: Amgen’s studies of Prostatic Neoplasms in search

CSPC Pharmaceutical Group in Prostatic Neoplasms: 1 program

  1. Docetaxelphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Prostatic Neoplasms in search

Asthmaall three · compare here

AstraZeneca in Asthma: 10 programs

  1. tozorakimabphase 3
  2. BFF MDIphase 3
  3. GP MDIphase 3
  4. londamocitinibphase 2
  5. sunakimentphase 2

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Asthma in search

Amgen in Asthma: 1 program

  1. AMG 691phase 1

Their studies: Amgen’s studies of Asthma in search

CSPC Pharmaceutical Group in Asthma: 1 program

  1. ocankitugphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Asthma in search

Neoplasmsall three · compare here

AstraZeneca in Neoplasms: 6 programs

  1. saruparibphase 3
  2. ceralasertibphase 3
  3. Leucovorinphase 2
  4. Ramucirumabphase 2
  5. AZD1390phase 1

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Neoplasms in search

Amgen in Neoplasms: 2 programs

  1. tarlatamabphase 3
  2. teprotumumabapproved, new study

Their studies: Amgen’s studies of Neoplasms in search

Renal Insufficiencyall three · compare here

AstraZeneca in Renal Insufficiency: 8 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. zibotentanphase 3
  4. balcinrenonephase 3
  5. opemalirsenphase 2

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Renal Insufficiency in search

Amgen in Renal Insufficiency: 1 program

  1. olpasiranphase 3

Their studies: Amgen’s studies of Renal Insufficiency in search

CSPC Pharmaceutical Group in Renal Insufficiency: 3 programs

  1. Sirolimusphase 3
  2. SYH2053phase 3
  3. aprocitentanphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Renal Insufficiency in search

Obesityall three · compare here

AstraZeneca in Obesity: 4 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD9550phase 2
  4. AZD1043phase 1

Their studies: AstraZeneca’s studies of Obesity in search

Amgen in Obesity: 1 program

  1. maridebart cafraglutidephase 3

Their studies: Amgen’s studies of Obesity in search

CSPC Pharmaceutical Group in Obesity: 5 programs

  1. edaglutide alfaphase 3
  2. SYH2069phase 2
  3. SYH2082phase 1
  4. SYH2092phase 1
  5. SYH9017phase 1

Their studies: CSPC Pharmaceutical Group’s studies of Obesity in search

Diabetes Mellitus, Type 2all three · compare here

AstraZeneca in Diabetes Mellitus, Type 2: 5 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD6793phase 2
  4. Elecoglipron Test formulation 1 Dose Aphase 1
  5. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus, Type 2 in search

Amgen in Diabetes Mellitus, Type 2: 2 programs

  1. maridebart cafraglutidephase 3
  2. AMG 127phase 1

Their studies: Amgen’s studies of Diabetes Mellitus, Type 2 in search

CSPC Pharmaceutical Group in Diabetes Mellitus, Type 2: 2 programs

  1. edaglutide alfaphase 3
  2. SYH2069phase 2

Their studies: CSPC Pharmaceutical Group’s studies of Diabetes Mellitus, Type 2 in search

Colorectal Neoplasmsall three · compare here

AstraZeneca in Colorectal Neoplasms: 1 program

  1. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Colorectal Neoplasms in search

Amgen in Colorectal Neoplasms: 2 programs

  1. sotorasibphase 3
  2. afliberceptphase 3

Their studies: Amgen’s studies of Colorectal Neoplasms in search

CSPC Pharmaceutical Group in Colorectal Neoplasms: 4 programs

  1. becotatugphase 3
  2. anbenitamab repodatecanphase 3
  3. Anti-PD-1/IL-15 Fusion Protein JMT108phase 2
  4. sintilimabphase 2

Their studies: CSPC Pharmaceutical Group’s studies of Colorectal Neoplasms in search

Small Cell Lung Carcinomaall three · compare here

AstraZeneca in Small Cell Lung Carcinoma: 2 programs

  1. tremelimumabphase 3
  2. durvalumabapproved, new study

Their studies: AstraZeneca’s studies of Small Cell Lung Carcinoma in search

Amgen in Small Cell Lung Carcinoma: 4 programs

  1. tarlatamabphase 3
  2. etakafusp alfaphase 1
  3. tambotatug pelitecanphase 1
  4. Zocilurtatug Pelitecanphase 1

Their studies: Amgen’s studies of Small Cell Lung Carcinoma in search

CSPC Pharmaceutical Group in Small Cell Lung Carcinoma: 1 program

  1. SYS6040phase 1

Their studies: CSPC Pharmaceutical Group’s studies of Small Cell Lung Carcinoma in search

Hyperlipidemiasall three · compare here

AstraZeneca in Hyperlipidemias: 3 programs

  1. laroprovstatphase 3
  2. Laroprovstat/ezetimibe FCDP-slow variantphase 1
  3. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Hyperlipidemias in search

Amgen in Hyperlipidemias: 1 program

  1. evolocumabapproved, new study

Their studies: Amgen’s studies of Hyperlipidemias in search

CSPC Pharmaceutical Group in Hyperlipidemias: 2 programs

  1. SYH2053phase 3
  2. bempedoic acidphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Hyperlipidemias in search

COVID-19all three · compare here

AstraZeneca in COVID-19: 1 program

  1. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of COVID-19 in search

Amgen in COVID-19: 1 program

  1. apremilastapproved, new study

Their studies: Amgen’s studies of COVID-19 in search

CSPC Pharmaceutical Group in COVID-19: 3 programs

  1. SYS6006 COVID-19 vaccinephase 2
  2. CHO cellphase 2
  3. palbociclibphase 1

Their studies: CSPC Pharmaceutical Group’s studies of COVID-19 in search

Dyslipidemiasall three · compare here

AstraZeneca in Dyslipidemias: 3 programs

  1. laroprovstatphase 3
  2. AZD4954phase 1
  3. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Dyslipidemias in search

Amgen in Dyslipidemias: 1 program

  1. evolocumabapproved, new study

Their studies: Amgen’s studies of Dyslipidemias in search

CSPC Pharmaceutical Group in Dyslipidemias: 1 program

  1. bempedoic acidphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Dyslipidemias in search

Show all 57

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: AstraZeneca 68 of 119 · Amgen 17 of 24 · CSPC Pharmaceutical Group 25 of 68 programs (60 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AstraZeneca: 5, CSPC Pharmaceutical Group: 3).